Comparative Pharmacology
Head-to-head clinical analysis: FLUORODOPA F18 versus METASTRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUORODOPA F18 versus METASTRON.
FLUORODOPA F18 vs METASTRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorodopa F18 is a radioactive diagnostic agent that is taken up by dopaminergic neurons in the striatum and converted by aromatic L-amino acid decarboxylase to fluorodopamine, which is stored in presynaptic vesicles. The emitted positrons allow for PET imaging to assess functional integrity of the nigrostriatal dopaminergic system.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
185-370 MBq (5-10 mCi) intravenous bolus injection for positron emission tomography imaging. Administered once per imaging session.
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 mCi) as a single injection.
None Documented
None Documented
110 minutes (physical half-life of F-18); biological half-life is approximately 2-3 hours, allowing imaging up to 4-6 hours post-injection.
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
Primarily renal excretion; approximately 70-80% of the injected dose is excreted unchanged in urine within 2 hours, with the remainder eliminated via biliary/fecal routes (<5%).
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical